Breakthrough: New Breast Cancer Drug Quadruples Survival Time in Phase 3 Trial, Sets Historic Efficacy Record

Celcuity (NASDAQ:CELC) announced breakthrough topline results from its Phase 3 VIKTORIA-1 trial, showing gedatolisib triplet therapy achieved an unprecedented 76% reduction in disease progression risk (median PFS 9.3 months vs. 2.0 months for control) in HR+/HER2- advanced breast cancer patients with PIK3CA wild-type. The doublet therapy also demonstrated significant efficacy (67% risk reduction, 7.4 months PFS), and both combinations exhibited better safety profiles than previous trials. These findings are particularly significant as gedatolisib is the first PI3K/AKT/mTOR inhibitor to show positive Phase 3 results in this patient population after CDK4/6 inhibitor failure, addressing a critical unmet need and positioning Celcuity for a Q4 2025 FDA New Drug Application.

Analysis

Celcuity's (NASDAQ: CELC) Phase 3 VIKTORIA-1 trial has yielded statistically significant and clinically meaningful results for its drug, gedatolisib, in treating HR+/HER2- advanced breast cancer for the PIK3CA wild-type cohort. The triplet therapy demonstrated an unprecedented 76% reduction in the risk of disease progression (Hazard Ratio=0.24), extending median progression-free survival (PFS) to 9.3 months compared to 2.0 months for the fulvestrant control arm. The doublet therapy was also highly effective, showing a 67% risk reduction (HR=0.33) and a 7.4-month median PFS. These results are particularly groundbreaking as gedatolisib is the first PI3K/AKT/mTOR pathway inhibitor to show positive Phase 3 results in this patient population, which has historically shown limited benefit from this class of drugs. Furthermore, the drug exhibited a favorable safety profile with lower treatment discontinuation rates and reduced instances of common side effects like hyperglycemia and stomatitis compared to earlier trials, enhancing its potential for clinical adoption. With plans to submit a New Drug Application to the FDA in Q4 2025, these results position gedatolisib as a potential paradigm-shifting treatment and a new standard of care for patients who have progressed after CDK4/6 inhibitor therapy, addressing a significant unmet medical need.

Key Decisions for Investors

• The exceptionally strong efficacy and favorable safety data significantly de-risk gedatolisib's clinical profile, supporting a bullish outlook on Celcuity as the drug could capture a substantial share of the HR+/HER2- advanced breast cancer market.
• Investors should monitor key upcoming catalysts, including the full data presentation later this year, topline results from the PIK3CA mutation cohort expected by the end of 2025, and the planned New Drug Application submission in Q4 2025.
• While the results are transformative, the timeline to potential commercialization is still over a year away, so investors should consider the execution risk associated with the regulatory approval process and the company's preparedness for a potential product launch.